AC Immune

AC Immune, a clinical-stage biopharmaceutical company, is focused on becoming a global leader in precision medicine for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The company's pioneering science is anchored by its two clinically validated technology platforms, SupraAntigen™ and Morphomer™, which fuel a diverse pipeline of nine therapeutic and three diagnostic candidates, with six currently in clinical trials. AC Immune's strong track record of securing strategic partnerships with leading global pharmaceutical companies, including Genentech, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., has resulted in substantial non-dilutive funding and potential milestone payments exceeding $3 billion. In 2023, AC Immune secured a significant $50.05M Post-IPO Equity investment, attracting prominent investors such as Redmile Group, BVF Partners, StemPoint Capital, and Avidity Partners. The company's commitment to breakthrough therapies and strategic partnerships positions it for further growth and innovation in the field of neurodegenerative diseases, emphasizing its potential as an attractive investment opportunity in the biotechnology and pharmaceutical industries. With its headquarters in Switzerland and a compelling portfolio of assets, AC Immune presents a compelling case for venture capital consideration.